293 related articles for article (PubMed ID: 16928403)
1. Glucagon-like peptide 2 inhibits ghrelin secretion in humans.
Banasch M; Bulut K; Hagemann D; Schrader H; Holst JJ; Schmidt WE; Meier JJ
Regul Pept; 2006 Dec; 137(3):173-8. PubMed ID: 16928403
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
Meier JJ; Nauck MA; Pott A; Heinze K; Goetze O; Bulut K; Schmidt WE; Gallwitz B; Holst JJ
Gastroenterology; 2006 Jan; 130(1):44-54. PubMed ID: 16401467
[TBL] [Abstract][Full Text] [Related]
3. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
[TBL] [Abstract][Full Text] [Related]
4. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
[TBL] [Abstract][Full Text] [Related]
5. Prandial regulation of ghrelin secretion in humans: does glucagon contribute to the preprandial increase in circulating ghrelin?
Soule S; Pemberton C; Hunt P; Cole D; Raudsepp S; Inder W
Clin Endocrinol (Oxf); 2005 Oct; 63(4):412-7. PubMed ID: 16181233
[TBL] [Abstract][Full Text] [Related]
6. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
[TBL] [Abstract][Full Text] [Related]
8. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
Lerche S; Soendergaard L; Rungby J; Moeller N; Holst JJ; Schmitz OE; Brock B
Clin Endocrinol (Oxf); 2009 Oct; 71(4):500-6. PubMed ID: 19094067
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion.
Hagemann D; Holst JJ; Gethmann A; Banasch M; Schmidt WE; Meier JJ
Regul Pept; 2007 Oct; 143(1-3):64-8. PubMed ID: 17434608
[TBL] [Abstract][Full Text] [Related]
10. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
11. Intravenous CCK-8, but not GLP-1, suppresses ghrelin and stimulates PYY release in healthy men.
Brennan IM; Otto B; Feltrin KL; Meyer JH; Horowitz M; Feinle-Bisset C
Peptides; 2007 Mar; 28(3):607-11. PubMed ID: 17129639
[TBL] [Abstract][Full Text] [Related]
12. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
Meier JJ; Goetze O; Anstipp J; Hagemann D; Holst JJ; Schmidt WE; Gallwitz B; Nauck MA
Am J Physiol Endocrinol Metab; 2004 Apr; 286(4):E621-5. PubMed ID: 14678954
[TBL] [Abstract][Full Text] [Related]
13. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects.
Toft-Nielsen M; Hvidberg A; Hilsted J; Dige-Petersen H; Holst JJ
Diabet Med; 1996 Jun; 13(6):544-8. PubMed ID: 8799658
[TBL] [Abstract][Full Text] [Related]
14. Effect of growth hormone on high plasma levels of glucagon-like peptide-1 (GLP-1) in hypophysectomized rats.
Tateishi K; Kitayama N; Ishikawa H; Mitsudome A; Hirose S
Exp Clin Endocrinol Diabetes; 2002 Oct; 110(7):361-3. PubMed ID: 12397536
[TBL] [Abstract][Full Text] [Related]
15. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
Prigeon RL; Quddusi S; Paty B; D'Alessio DA
Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
[TBL] [Abstract][Full Text] [Related]
16. Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations.
Lucidi P; Murdolo G; Di Loreto C; Parlanti N; De Cicco A; Fatone C; Taglioni C; Fanelli C; Broglio F; Ghigo E; Bolli GB; Santeusanio F; De Feo P
Nutr Metab Cardiovasc Dis; 2005 Dec; 15(6):410-7. PubMed ID: 16314227
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males.
Jeibmann A; Zahedi S; Simoni M; Nieschlag E; Byrne MM
Eur J Clin Invest; 2005 Sep; 35(9):565-72. PubMed ID: 16128863
[TBL] [Abstract][Full Text] [Related]
18. Effects of gastric emptying on the postprandial ghrelin response.
Blom WA; Lluch A; Vinoy S; Stafleu A; van den Berg R; Holst JJ; Kok FJ; Hendriks HF
Am J Physiol Endocrinol Metab; 2006 Feb; 290(2):E389-95. PubMed ID: 16188911
[TBL] [Abstract][Full Text] [Related]
19. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
20. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans.
Meier JJ; Holst JJ; Schmidt WE; Nauck MA
Am J Physiol Endocrinol Metab; 2007 Sep; 293(3):E849-56. PubMed ID: 17609256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
